Modoki

2024年12月 多発性骨髄腫（BJλ型）の確定診断。R-ISS分類 Stage Ⅱ。第一腰椎圧迫骨折あり。2025年1月〜VRD療法。4月幹細胞採取。6月自家移植。10月〜維持療法。仕事と趣味に加えてMM治療という目標が加わり、目下生き方改善中。情報収集と備忘録メモ用アカウント。ゆっくりのんびり

[Modoki @AshuraModoki]

再発・難治性多発性骨髄腫に同種BCMA標的CAR-T細胞療法CB-011は良好な安全性と有望な効果を示す可能性【EHA 2026】
https://t.co/xyQmivrNvi

[Ankit kansagra @kansagraMD]

Iber-DVD in Newly Diagnosed Multiple Myeloma ! Early and exciting data by @MyelomaDrKapoor et al. Congratulations! I love seeing more data on small molecules in MM were the field is now seeing a monumental shift towads T-cell directed therapies ! Such a huge unmeet need in community oncology.

Question we are going to beasked - are we going to see improvement in induction therapy with novel small molecules esp in TE NDMM; OR with generic Len and better consolidation, e.g., CAR-T and Bispecifics, we will see the field moving in a different direction ??

Exciting times ahead!
#EHA2026

[Drug Designer B @DesignCureAll]

GPRC5D×CD3二重特異性抗体タルケタマブ併用が第3相で標準治療DPdを上回る。24カ月PFSは81.3%/77.6%対51.2%、病勢進行・死亡リスクを最大72%低下。
#NEJM #多発性骨髄腫 #二重特異性抗体 #Talquetamab #GPRC5D
https://t.co/AFqHxglIKY

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

MajesTEC-4 was the most fascinating study reported at EHA 2026 for me.

Not because 100% MRD negativity (10⁻⁵) was achieved.

What truly caught my attention was the magnitude and speed of CR/sCR conversion.

After ASCT, CR/sCR rates were approximately 25-40%.

Within 6-12 months of Tec-based maintenance, CR/sCR approached 100%.

That is breathtaking.

MASTER, CASSIOPEIA, and PERSEUS established an extraordinarily high bar. MajesTEC-4 is now challenging those landmark studies despite being an early run-in cohort of ~90 patients.

The deeper question is not whether teclistamab is active.

We already know it is.

The question is why it appears so active in the post-ASCT setting.

Where do the effector T cells come from?

Are they predominantly reinfused with the autograft?

Do the classic Mayo observations linking early lymphocyte recovery to superior outcomes offer a clue?

Perhaps ASCT is doing more than cytoreduction.

Perhaps maintenance is doing more than maintaining.

Step by step.
Trial by trial.

Not only are responses becoming deeper.

More patients are achieving them, and they are achieving them faster.

#EHA26 #MultipleMyeloma #ASCT #MRD #Myeloma

[Modoki @AshuraModoki]

@BKRIZE11 祝目標達成！
ともにしぶとく頑張りましょう💪

[がんナビ通信 @cancer_navi]

欧州血液学会からの速報です。再発または難治性多発性 #骨髄腫 で1-3レジメンの治療歴がある患者に対し、GPRC5D標的CAR-T細胞療法arlocabtagene autoleucelの単回投与は、忍容性があり、深く持続的な効果があることが報告されました。 #EHA26
https://t.co/PvIS4fdxEL

[がんナビ通信 @cancer_navi]

欧州血液学会からの速報です。治療歴の多い再発または難治性多発性 #骨髄腫 に対し、健康なドナーのT細胞から製造されたBCMA標的CAR-T細胞療法CB-011は、深く持続的な効果と管理可能な安全性プロファイルを示したことが、フェーズ1試験の結果から示されました。 #EHA26
https://t.co/oXyklfG9Jg

[Mostafa Faisal @MostafaFaisal14]

MajesTEC-3 vs MonumenTAL-3

[Raul Cordoba, MD, PhD #EHA2026 @DrRaulCordoba]

#EHA2026 Better response rate with bispecific antibodies based bridging therapy before #CARTcell, mostly Glofitamab-GEMOX #lymsm

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

🦴 MajesTEC-4 (a post transplant maintenance trial) May Delay the Retirement of ASCT 😱

Fellow:

“Professor, with CARTITUDE-4, MajesTEC-3, MajesTEC-9, MonumenTAL-3, and future frontline studies such as MajesTEC-5/7, I think High-Dose Melphalan + AutoSCT will be honorably discharged soon!”

Professor:

“Not so fast.”

The updated MajesTEC-4 Safety Run-In (SRI) cohorts reported:

✅ Nearly 100% CR
✅ Nearly 100% MRD negativity
✅ Median PFS not reached
✅ Only 3 progressions reported

Importantly, MajesTEC-4 remains an ongoing Phase III study and the randomized portion is still actively enrolling.

Still, these data raise an interesting biological question.

For years, we viewed AutoSCT primarily as a delivery system for high-dose melphalan.

Perhaps it is more than that.

Perhaps HDM + AutoSCT serves as a platform for the next generation of immunotherapy through:

🦴 Deep cytoreduction

🦴 Marrow niche disruption

🧬 Immune ecosystem reset

🚀 An optimal setting for maintenance immunotherapy

First it was lenalidomide maintenance.

Now it may be teclistamab ± lenalidomide.

Whether this hypothesis is correct remains to be proven, but MajesTEC-4 certainly makes the discussion more interesting.

Perhaps AutoSCT is not the treatment.

🚀 Perhaps AutoSCT is the launchpad.

AutoSCT may stay around longer than me. 😄

#EHA2026 #Myeloma #Bispecifics

[日本がん対策新聞@かんぱち編集長 @gantaisaku1105]

【多発性骨髄腫】近い将来、再発・難治性多発性骨髄腫で使用可能になるレジメンの整理
1)テクベイリ＋タービー
2)テクベイリ＋ダラキューロ
3)テクベイリ(2L)
4)タービー＋ダラキューロ＋ポマリスト
5)タービー＋ダラキューロ
6)メジグドミド＋カイプロリス＋デキサメタゾン
https://t.co/ML54tuck3b

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #EHA2026 | PRESENTATION

Niels van de Donk presents updated safety run-in results from the MajesTEC-4 study evaluating teclistamab ± lenalidomide versus lenalidomide alone as post-transplant maintenance for NDMM.
Teclistamab-based maintenance was associated with grade 1/2 CRS events only and no cases of ICANS. During maintenance, ≥CR rates were 96.7–100% across cohorts, with MRD-negative CR rates at 12 months of 90–100% among evaluable patients. Median PFS was not reached in any cohort, with estimated 24-month PFS rates of 94–96.6%.

Follow our live feed for more updates: https://t.co/IjiLwPfcB5

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#MultipleMyeloma #myeloma #mmsm #MedEd @amsterdamumc

[Modoki @AshuraModoki]

CB-011

再発・難治性の多発性骨髄腫を対象とした同種（他家）CAR T細胞療法

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #EHA2026 | PRESENTATION

Binod Dhakal presents long-term follow-up results from the phase I CaMMouflage trial evaluating CB-011, an allogeneic anti-BCMA CAR T-cell therapy with immune cloaking, for the treatment of RRMM (N = 48).
Among BCMA-naïve patients treated at the recommended expansion dose (450M CAR-T cells; n = 12), CB-011 demonstrated an ORR of 92% and a ≥CR rate of 83%. MRD negativity (10^-5) was observed in 91% of evaluable patients (n = 11). Grade ≥3 infections and CRS occurred in 25% and 8%, respectively. There were no instances of GvHD, IEC-EC, parkinsonism, or cranial nerve palsies. Enrolment in the dose-expansion portion is ongoing in both BCMA-naïve and BCMA-exposed patients.

Follow our live feed for more updates: https://t.co/IjiLwPfcB5

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#MultipleMyeloma #myeloma #mmsm #MedEd @bhemato

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#EHA2026 and congrats #cyrilletouzeau and the whole MajesTEC-9 team for such excellent results!

Tec monotherapy joins our growing landscape of excellent treatment options as early as first relapse 👏

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#EHA2026 a new standard of care about to emerge in myeloma!

@PlasmaCellPete looking as presidential as ever at the plenary session 💪

MonumenTAL-3: tal-dara +/- pom versus Dara-Pd.

Tal-DP and tal-D both dramatically outperformed D-Pd!

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #EHA2026 | PRESENTATION

Rahul Banerjee presents results from an analysis of the phase III MajesTEC-3 study evaluating teclistamab plus daratumumab (Tec-Dara) in patients with RRMM, stratified by cytogenetic and functional risk.
Tec-Dara improved PFS versus DPd/DVd across all cytogenetic and functional risk groups. In patients with prespecified HR cytogenetics, median PFS was not reached with Tec-Dara versus 14.4 months with DPd/DVd (HR, 0.15), while estimated 36-month PFS rates were 77.7% versus 11.5%, respectively. Tec-Dara also increased MRD-negative ≥CR rates across risk groups, including among patients with functional high-risk disease (42.9% vs 5.6% at 10⁻⁵sensitivity; OR, 12.75).

Follow our live feed for more updates: https://t.co/IjiLwPfKqD

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#MultipleMyeloma #myeloma #mmsm #MedEd @RahulBanerjeeMD

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #EHA2026 | PRESENTATION

Prashant Kapoor presents results from the phase I/II IDEAL study evaluating iberdomide-based quadruplet therapy for NDMM (N = 44).
The ORR was 100%. The CR rate increased from 43% at induction to 57% at deepest response, while the MRD-negative CR rate increased from 34% to 52%. At a median follow-up of 22.8 months, 12- and 18-month PFS rates were 92.0% and 88.9%, respectively, and 12- and 18-month OS rates were 97.4% and 94.5%. The most common Grade 3 and 4 TEAE was neutropenia (40.9% and 18.2%). 29.5% required G-CSF support.

Follow our live feed for more updates: https://t.co/IjiLwPfKqD

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#MultipleMyeloma #myeloma #mmsm #MedEd

[日本の研究.comニュース @rjp_news]

【注目プレスリリース】多発性骨髄腫の治療に使われる二重特異性抗体に反応して 一部の免疫細胞だけが大きく増えることを解明 ～「血液のがん」治療の効果増強法開発に期待～ / 大阪大学 https://t.co/uNtB69amBC

[Modoki @AshuraModoki]

再発・難治性多発性骨髄腫への新戦略：テクリスタマブとダラツムマブ併用療法の劇的な効果（MajesTEC-3試験） | 柏五味歯科内科リウマチクリニックブログ https://t.co/5OC7lzep0x